Month: July 2024

Wealth Pinnacle: Leading the Next Generation of Futures Investment Strategies

With the vigorous development of global financial markets, the futures market, as a hotspot for investors seeking profits, has increasingly become the focus of attention across various sectors. In this challenging yet opportunistic environment, Wealth Pinnacle Technology Service Co. Ltd. (referred to as Wealth Pinnacle) has emerged, dedicated to providing cutting-edge data technology services to global traders, empowering them to achieve optimized investment returns in a fiercely competitive market.

Showcasing Strength: Technological Innovation Leading the Futures Market

Wealth Pinnacle, positioned in Southeast Asia with a global outlook, has established a strong reputation worldwide through its outstanding technological capabilities and profound industry experience. It has not only assembled top analysts and traders in the financial markets but also pioneered an integrated intelligent strategy system through continuous technological innovation and data optimization, offering comprehensive support for futures trading.

Service Value: Customized Trading Strategy Sharing and Educational Support

At Wealth Pinnacle, we recognize the diverse needs of every trader. Therefore, we not only provide traditional data analysis and market information services but also focus on tailoring the most suitable trading strategies through in-depth market analysis and acute market insights. The platform serves not only as an information tool but also as a community for sharing experiences and learning the latest market trends globally, enhancing traders’ skills and decision-making abilities.

Technological Advantages: Introduction of AI Intelligent Strategy System

In the era of information explosion, the ability to quickly and accurately acquire and utilize data is crucial to determining investment success. Wealth Pinnacle has introduced advanced artificial intelligence and big data analytics technologies to build an efficient AI intelligent strategy system. This system not only monitors market fluctuations in real-time but also predicts future trends based on deep learning algorithms, providing traders with scientific and precise decision-making support. Through intelligent data processing and personalized recommendation services, we help users capture market opportunities more swiftly, reduce trading risks, and achieve long-term stable investment returns.

Global Expansion: Building a Diversified International Service Platform

As a global futures data service platform, Wealth Pinnacle extends its reach beyond Southeast Asia to North America, Europe, and emerging markets. We actively collaborate closely with futures exchanges and financial institutions worldwide, committed to promoting and applying advanced technologies and services. Moving forward, we will continue to strengthen international cooperation, expand business outreach, and provide a broader and higher-quality futures data service for global traders.

Service Commitment: User Experience Foremost, Continuous Innovation Driving Development

At Wealth Pinnacle, user experience is always a core focus. We continuously enhance platform trading experiences and functionalities to ensure users can utilize services effortlessly and efficiently. Simultaneously, we invest continuously in technological research and development, tracking industry trends closely, and continuously updating and optimizing our intelligent systems to adapt to rapid market changes and diverse user needs.

Wealth Pinnacle, with its outstanding capabilities, leading technology, and dedicated service, is becoming the preferred partner for global futures traders. We firmly believe that through innovation, intelligence, and a global strategy, Wealth Pinnacle will continue to lead the trend in the futures market, creating more opportunities for wealth enhancement for you. Together, let’s strive for excellence and share success!

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Wealth Pinnacle Technology Service Co. Ltd.
Contact Person: John Mitchell
Email: Send Email
Country: Vietnam
Website: WealthPinnacle.info

Global Smart Futures: Wealth Pinnacle Unlocks a New Realm of Investment for Users

With the vigorous development of global financial markets, the futures market, as a hotspot for investors seeking profits, has increasingly become the focus of attention across various sectors. In this challenging yet opportunistic environment, Wealth Pinnacle Technology Service Co. Ltd. (referred to as Wealth Pinnacle) has emerged, dedicated to providing cutting-edge data technology services to global traders, empowering them to achieve optimized investment returns in a fiercely competitive market.

Showcasing Strength: Technological Innovation Leading the Futures Market

Wealth Pinnacle, positioned in Southeast Asia with a global outlook, has established a strong reputation worldwide through its outstanding technological capabilities and profound industry experience. It has not only assembled top analysts and traders in the financial markets but also pioneered an integrated intelligent strategy system through continuous technological innovation and data optimization, offering comprehensive support for futures trading.

Service Value: Customized Trading Strategy Sharing and Educational Support

At Wealth Pinnacle, we recognize the diverse needs of every trader. Therefore, we not only provide traditional data analysis and market information services but also focus on tailoring the most suitable trading strategies through in-depth market analysis and acute market insights. The platform serves not only as an information tool but also as a community for sharing experiences and learning the latest market trends globally, enhancing traders’ skills and decision-making abilities.

Technological Advantages: Introduction of AI Intelligent Strategy System

In the era of information explosion, the ability to quickly and accurately acquire and utilize data is crucial to determining investment success. Wealth Pinnacle has introduced advanced artificial intelligence and big data analytics technologies to build an efficient AI intelligent strategy system. This system not only monitors market fluctuations in real-time but also predicts future trends based on deep learning algorithms, providing traders with scientific and precise decision-making support. Through intelligent data processing and personalized recommendation services, we help users capture market opportunities more swiftly, reduce trading risks, and achieve long-term stable investment returns.

Global Expansion: Building a Diversified International Service Platform

As a global futures data service platform, Wealth Pinnacle extends its reach beyond Southeast Asia to North America, Europe, and emerging markets. We actively collaborate closely with futures exchanges and financial institutions worldwide, committed to promoting and applying advanced technologies and services. Moving forward, we will continue to strengthen international cooperation, expand business outreach, and provide a broader and higher-quality futures data service for global traders.

Service Commitment: User Experience Foremost, Continuous Innovation Driving Development

At Wealth Pinnacle, user experience is always a core focus. We continuously enhance platform trading experiences and functionalities to ensure users can utilize services effortlessly and efficiently. Simultaneously, we invest continuously in technological research and development, tracking industry trends closely, and continuously updating and optimizing our intelligent systems to adapt to rapid market changes and diverse user needs.

Wealth Pinnacle, with its outstanding capabilities, leading technology, and dedicated service, is becoming the preferred partner for global futures traders. We firmly believe that through innovation, intelligence, and a global strategy, Wealth Pinnacle will continue to lead the trend in the futures market, creating more opportunities for wealth enhancement for you. Together, let’s strive for excellence and share success!

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Wealth Pinnacle Technology Service Co. Ltd.
Contact Person: John Mitchell
Email: Send Email
Country: Vietnam
Website: WealthPinnacle.info

Wealth Pinnacle: Leading the Intelligent Future of Futures Trading

With the vigorous development of global financial markets, the futures market, as a hotspot for investors seeking profits, has increasingly become the focus of attention across various sectors. In this challenging yet opportunistic environment, Wealth Pinnacle Technology Service Co. Ltd. (referred to as Wealth Pinnacle) has emerged, dedicated to providing cutting-edge data technology services to global traders, empowering them to achieve optimized investment returns in a fiercely competitive market.

 

Showcasing Strength: Technological Innovation Leading the Futures Market

Wealth Pinnacle, positioned in Southeast Asia with a global outlook, has established a strong reputation worldwide through its outstanding technological capabilities and profound industry experience. It has not only assembled top analysts and traders in the financial markets but also pioneered an integrated intelligent strategy system through continuous technological innovation and data optimization, offering comprehensive support for futures trading.

Service Value: Customized Trading Strategy Sharing and Educational Support

At Wealth Pinnacle, we recognize the diverse needs of every trader. Therefore, we not only provide traditional data analysis and market information services but also focus on tailoring the most suitable trading strategies through in-depth market analysis and acute market insights. The platform serves not only as an information tool but also as a community for sharing experiences and learning the latest market trends globally, enhancing traders’ skills and decision-making abilities.

Technological Advantages: Introduction of AI Intelligent Strategy System

In the era of information explosion, the ability to quickly and accurately acquire and utilize data is crucial to determining investment success. Wealth Pinnacle has introduced advanced artificial intelligence and big data analytics technologies to build an efficient AI intelligent strategy system. This system not only monitors market fluctuations in real-time but also predicts future trends based on deep learning algorithms, providing traders with scientific and precise decision-making support. Through intelligent data processing and personalized recommendation services, we help users capture market opportunities more swiftly, reduce trading risks, and achieve long-term stable investment returns.

Global Expansion: Building a Diversified International Service Platform

As a global futures data service platform, Wealth Pinnacle extends its reach beyond Southeast Asia to North America, Europe, and emerging markets. We actively collaborate closely with futures exchanges and financial institutions worldwide, committed to promoting and applying advanced technologies and services. Moving forward, we will continue to strengthen international cooperation, expand business outreach, and provide a broader and higher-quality futures data service for global traders.

Service Commitment: User Experience Foremost, Continuous Innovation Driving Development

At Wealth Pinnacle, user experience is always a core focus. We continuously enhance platform trading experiences and functionalities to ensure users can utilize services effortlessly and efficiently. Simultaneously, we invest continuously in technological research and development, tracking industry trends closely, and continuously updating and optimizing our intelligent systems to adapt to rapid market changes and diverse user needs.

Wealth Pinnacle, with its outstanding capabilities, leading technology, and dedicated service, is becoming the preferred partner for global futures traders. We firmly believe that through innovation, intelligence, and a global strategy, Wealth Pinnacle will continue to lead the trend in the futures market, creating more opportunities for wealth enhancement for you. Together, let’s strive for excellence and share success!

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Wealth Pinnacle Technology Service Co. Ltd.
Contact Person: John Mitchell
Email: Send Email
Country: Vietnam
Website: WealthPinnacle.info

Optometry Equipment Market worth $6.1 billion by 2029 | MarketsandMarkets™

“This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies.”
Browse 321 market data Tables and 43 Figures spread through 290 Pages and in-depth TOC on “Optometry Equipment Market by Type (OCT, Ophthalmoscope, Autorefractor, Tonometer, Slitlamp, Wavefront Analyzer), Application (General Examination, Cataract, Glaucoma,), End User (Eye Clinics, Hospitals), and Region – Global Forecast to 2029

Optometry Equipment Market in terms of revenue was estimated to be worth $4.5 billion in 2024 and is poised to reach $6.1 billion by 2029, growing at a CAGR of 6.4% from 2024 to 2029 according to a new report by MarketsandMarkets™. The principal drivers propelling the expansion of this market are the growing prevalence of eye illnesses, advancements in ophthalmic device technology, expanding government initiatives aimed at preventing visual impairment, growing healthcare expenses, and rising disposable incomes. Companies in the market for optometry equipment are finding that developing nations like China, Japan, and India provide attractive opportunities.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14475790

The retina and glaucoma examination products segment hold the largest share of the optometry equipment market, by type

According to product type, the worldwide optometry equipment market is divided into three segments: goods for general examinations, cornea and cataract examinations, and products for glaucoma and retinal examinations. In2023, the optometry equipment market was dominated by the sector that produced examination goods for glaucoma and retina. The significant portion of the market is due to a variety of factors, including the expansion of clinics, the increasing incidence of glaucoma and retinal disorders, the easier availability to modern ophthalmic diagnostic technologies, and technological advancements in optometry equipment.

General examination segment responsible for the largest share in the market, by application

The market for optometry equipment is divided into segments based on applications, including age-related macular degeneration, cataract surgery, glaucoma, and general exams. As of 2023, the worldwide optometry equipment market was dominated by the general examination segment. The primary factors influencing this segment’s size include the aging population, the rise in the prevalence of eye diseases, and the number of cases of diabetes and hypertension.

The eye clinics segment held the largest share in the market, by end user.

By end user, the optometry equipment market is divided into eye clinics, hospitals, and other consumers. The sector that held the biggest share of the global optometry equipment market in 2023 was clinics. This sector makes up a sizeable share of the market because of the vast number of patients treated in clinics and the increasing number of private clinical practices founded by ophthalmologists in emerging countries.

North America aimed for the largest share of the optometry equipment market.

There are five main regions that make up the global market for optometry equipment: North America, Europe, Asia Pacific, and Rest of the World (which includes Latin America, the Middle East & Africa, and GCC countries). In terms of market share, North America led the optometry equipment market in 2023. Some of the contributing factors are the rising prevalence of ocular diseases, the rapidly aging population, the accessibility of state-of-the-art optometry equipment, and the growing utilization of ophthalmology procedures and therapies in this field.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=14475790

Optometry Equipment Market Dynamics:

Drivers:

  1. Increasing incidence of eye disordersa. Cataractsb. Glaucoma
  2. Technological advancements in ophthalmic devices
  3. Rising government initiatives to control visual impairment
  4. Increasing healthcare expenditure

Restraints:

  1. High cost of optometry equipment
  2. Growing adoption of refurbished optometry equipment

Opportunities:

  1. Growth opportunities in emerging markets

Challenge:

  1. Growth opportunities in emerging markets

Key Market Players of Optometry Equipment Industry:

The major players leading in optometry equipment market are Carl Zeiss Meditec AG (Germany), EssilorLuxottica (France), Alcon (Switzerland), Topcon Corporation (Japan), Bausch Health Companies Inc. (Canada), NIDEK Co. Ltd. (Japan), Canon Inc. (Japan), Johnson and Johnson (US), HEINE Optotechnik (Germany), Revenio Group PLC (Finland), Haag-Streit Group (Switzerland) and Heidelberg Engineering (Germany).

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
  • By Designation: C-level (27%), Director-level (18%), and Others (55%)
  • By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%), and Middle East & Africa(4%)

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=14475790

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/optometry-eye-exam-equipment-market-14475790.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Optometry Equipment Market worth $6.1 billion by 2029 | MarketsandMarkets™

Pancreatic Cancer Pipeline 2024 | ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics

DelveInsight’s, “Pancreatic Cancer Pipeline Insight 2024” report provides comprehensive insights about 290+ companies and 300+ pipeline drugs in the Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Pancreatic Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Pancreatic Cancer Pipeline Outlook

Key Takeaways from the Pancreatic Cancer Pipeline Report

  • July 2024:- Trishula Therapeutics, Inc.- An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients Not Previously Treated for Metastatic Pancreatic Adenocarcinoma.
  • June 2024:- Cantex Pharmaceuticals– A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer. This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.
  • DelveInsight’s Pancreatic Cancer pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.
  • The leading Pancreatic Cancer Companies such as ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
  • Promising Pancreatic Cancer Pipeline Therapies such as Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.

Stay ahead with the most recent pipeline outlook for Pancreatic Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pancreatic Cancer Treatment Drugs

 

Pancreatic Cancer Emerging Drugs Profile

Pamrevlumab: FibroGen

Pamrevlumab is a potential first-in-class antibody being developed by FibroGen that inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The U.S. Food and Drug Administration has granted Orphan Drug Designation, and Fast Track designation to Pamrevlumab for the treatment of patients with pancreatic cancer. Currently it is in Phase III stage of clinical trial evaluation to treat Pancreatic Cancer.

Devimistat: Cornerstone Pharmaceuticals

CPI-613 (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth. Cancer progresses because it utilizes the mitochondria – the energy machinery of the cells – to generate the building blocks of the next tumor in order to fuel cancer growth and proliferation. Because it is designed to be highly specific, minimally toxic and effective against a wide variety of cancers, devimistat can be used for recurrent and hard-to-treat cancers, including on a chronic basis; it may also enhance the sensitivity of cancer cells to other treatment modalities, including chemotherapy. Currently, the drug is in Phase III stage of its development for the treatment of pancreatic cancer.

Masitinib: AB Science

Masitinib is a highly selective inhibitor of mast cell which gives therapeutic benefit by impacting on mast cell related remodeling of the tumor microenvironment. Masitinib is being developed in combination with chemotherapies for treatment of malignancies through its immunotherapeutic properties. The increased mast cell activity within the tumor microenvironment can promote disease progression through release of numerous pro-tumoral mediators, down-regulate the immune response to tumors, and modulation of macrophages towards a pro-tumoral state. The inhibition of the mast cell activity results in anti-tumor effect.

SBP-101: Panbela Therapeutics

Ivospemin (SBP-101) is a proprietary polyamine analogue that, due to its unique chemical structure. It inhibits both S-adenosylmethionine decarboxylase 1 (AMD1) and ornithine decarboxylase 1 (ODC1), two key enzymes in polyamine biosynthesis, lowering intracellular polyamine concentrations and slowing or preventing targeted cell growth and division. Ivospemin provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity. The polyamine pathway at complementary junctions alter the disease. In particular, the drug have the potential to suppress and prevent tumor growth, enhance anti-tumor activity of other anti-cancer agents, and modulate the immune system. Currently, the drug is in Phase II/III stage of its development for the treatment of pancreatic cancer.

TAS-102: Taiho Pharmaceutical Co., Ltd.

TAS-102 (Lonsurf) is an oral anticancer drug, which utilizes the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity and differs from conventional fluoropyrimidines. FTD is an antineoplastic nucleoside analogue, which is incorporated directly into the DNA, thereby interfering with the function of DNA. The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase. The drug is currently in Phase II trial for the pancreatic cancer.

RAIN-32: Rain Oncology

RAIN-32 (Milademetan), an oral small molecule, inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, and loss of an MDM2 regulator or other mechanism. The company commenced an additional Phase II trial in a multicenter, single arm, open-label, and basket trial evaluating milademetan for the treatment of MDM2-amplified advanced solid tumors (MANTRA-2) including pancreatic cancer.

IMX-110: Immix Biopharma

IMX-110 is a Tissue-Specific Therapeutic™ built on ImmixBio’s TME Normalization™ Technology encapsulating a poly-kinase inhibitor and apoptosis inducer delivered deep into the tumor micro-environment, or TME. ImmixBio’s TME Normalization Technology enables IMX-110 to circulate in the bloodstream, then exit through porous tumor blood vessels, and accumulate in the TME. IMX-110 then simultaneously attacks all 3 components of the TME (cancer associated fibroblasts, or CAFs; tumor-associated macrophages/immune cells, or TAMs, and cancer itself), severing the critical lifelines between the tumor and its metabolic and structural support. IMX-110’s TME Normalization Technology causes tumor apoptosis, a non-inflammatory tumor-cell death (vs. necroptosis, which results in repeat reignition of the inflammatory cascade leading to tumor progression).

Explore groundbreaking therapies and clinical trials in the Pancreatic Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Pancreatic Cancer Drugs

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Pancreatic Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Pancreatic Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Pancreatic Cancer Market Drivers and Barriers

Scope of the Pancreatic Cancer Pipeline Report

  • Coverage- Global
  • Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Pancreatic Cancer Companies- ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
  • Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.

Get the latest on Pancreatic Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Pancreatic Cancer Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Pancreatic Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pancreatic Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pamrevlumab: FibroGen
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Niraparib: Innovent Biologics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. CT041: CARsgen Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ONC 212: Oncoceutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Pancreatic Cancer Key Companies
  21. Pancreatic Cancer Key Products
  22. Pancreatic Cancer- Unmet Needs
  23. Pancreatic Cancer- Market Drivers and Barriers
  24. Pancreatic Cancer- Future Perspectives and Conclusion
  25. Pancreatic Cancer Analyst Views
  26. Pancreatic Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Cancer Pipeline 2024 | ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics

Breast Cancer Pipeline 2024 | Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd.

DelveInsight’s, “Breast Cancer Pipeline Insight 2024” report provides comprehensive insights about 120+ Breast Cancer companies and 130+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Breast Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Breast Cancer Pipeline Outlook

Key Takeaways from the Breast Cancer Pipeline Report

  • July 2024:- Eli Lilly and Company– EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy. The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).
  • July 2024:- Seagen Inc.- A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination With Other Anticancer Therapies in Solid Tumors. This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they’ve grown bigger in one spot or spread to other parts of the body, they’re harder to treat. This is called advanced or metastatic cancer.
  • July 2024:- MedSIR– Phase II Study for PIK3CA/PTEN-altered Advanced Metaplastic Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin. The multicenter, two-cohort, non-comparative, open-label, phase II clinical trial SABINA aims to analyze the safety and efficacy of MEN1611 in monotherapy and in combination with eribulin, a non-taxane chemotherapy agent, in Hormone Receptor (HR)-known/Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolog (PTEN)-altered, unresectable locally advanced or metastatic metaplastic breast carcinoma (MpBC) patients.
  • July 2024:- Hoffmann-La Roche– A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer.
  • DelveInsight’s Breast Cancer pipeline report depicts a robust space with 120+ Breast Cancer companies working to develop 130+ pipeline therapies for Breast Cancer treatment.
  • The leading Breast Cancer Companies working in the market include Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
  • Promising Breast Cancer Pipeline Therapies in the various stages of development includes Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.

Stay ahead with the most recent pipeline outlook for Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Breast Cancer Treatment

Breast Cancer Emerging Drugs Profile

  • SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.

SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a topoisomerase I payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death. It can bind to the cell membrane surface of HER2 expressing cells, and then enter the cells to reach the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells. Preclinical research results show that SHR-A1811 has good anti-tumor activity, safety, tolerability and pharmacokinetic characteristics, or can further improve drug resistance, enhance efficacy, meet clinical needs, and provide more cancer patients multiple choice. Currently, the drug is in the Phase III stage of its development for the treatment of Breast Cancer.

  • HLX11: Shanghai Henlius Biotech

HLX11 is a pertuzumab biosimilar developed by Henlius independently in line with relevant regulations and guidelines on biosimilars in China and the European Union (EU), which can be potentially used in combination with trastuzumab and chemotherapy as neoadjuvant or adjuvant treatment for HER2-positive early breast cancer and in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic or unresectable locally recurrent breast cancer patients. HLX11 can specifically bind with the subdomain II of HER2 extracellular domain and inhibit the heterodimerisation of HER2 and other HER family receptors, i.e., EGFR, HER3, and HER4. This will inhibit signal transduction of relevant pathways and lead to the stop of growth and apoptosis of tumour cells. In the meantime, HLX11 can also enhance the tumour-killing activity of immune cells via antibody-dependent cell cytotoxicity. Currently, the drug is in the Phase III stage of its development for the treatment of HER2 positive Breast Cancer.

  • Praluzatamab ravtansine: CytomX Therapeutics

Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. The tumor microenvironment is enriched for proteases capable of cleaving the linker, thereby releasing the mask, allowing for localized binding of CX-2009 to CD166. Currently, the drug is in the Phase II stage of its development for the treatment of Breast Cancer.

  • MCLA-128: Merus N.V.

MCLA-128 is an antibody-dependent cell-mediated cytotoxicity (ADCC) -enhanced Biclonics® that utilizes Merus Dock & Block® mechanism and inhibits the neuregulin/HER3 tumor-signaling pathway in solid tumors. MCLA-128 is believed to target the HER3 signaling pathway and to overcome the resistance of tumor cells to HER2-targeted therapies using two mechanisms: blocking growth and survival pathways to stop tumor expansion and recruitment and enhancement of immune effector cells to eliminate the tumor. The therapeutic candidate is a full-length IgG bi-specific antibody that acts by targeting HER2 and HER3. It is an antibody-dependent cellular cytotoxicity (ADCC)-enhanced Biclonic, which is developed based on Biclonics ENGAGE platform. Currently the drug is in the Phase II stage of clinical trial evaluation for the treatment of Breast Cancer.

  • DX126 262: Hangzhou DAC Biotech

DX-126262 is under development for the treatment of HER2-positive or HER2-mutated unresectable locally advanced or metastatic non-squamous NSCLC, Breast Cancer, breast cancer. The drug candidate is an antibody drug conjugate comprising recombinant humanized anti-Her2 monoclonal antibody conjugated to Tub-114. It is formulated as lyophilized powder and administered via intravenous route of administration. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of HER2-positive Breast Cancer.

Explore groundbreaking therapies and clinical trials in the Breast Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Breast Cancer Drugs

Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical 

Breast Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Breast Cancer Market Drivers and Barriers

Scope of the Breast Cancer Pipeline Report

  • Coverage- Global
  • Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
  • Breast Cancer Pipeline Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
  • Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Breast Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Breast Cancer Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Breast Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MCLA-128: Merus N.V.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. DX126 262: Hangzhou DAC Biotech
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ES2B C001: ExpreS2ion Biotechnologies
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Breast Cancer Companies
  21. Breast Cancer Products
  22. Breast Cancer Unmet Needs
  23. Breast Cancer Market Drivers and Barriers
  24. Breast Cancer Future Perspectives and Conclusion
  25. Breast Cancer Analyst Views
  26. Breast Cancer Companies
  27. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Breast Cancer Pipeline 2024 | Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd.

Esophageal Cancer Pipeline 2024 | BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company

DelveInsight, “Esophageal Cancer Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Esophageal Cancer pipeline landscape. It covers the Esophageal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Esophageal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Esophageal Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Esophageal Cancer Pipeline Outlook

Key Takeaways from the Esophageal Cancer Pipeline Report

  • July 2024:- AstraZeneca- A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors.
  • July 2024;- Seagen- A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers. This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It will look at what side effects happen when participants take this combination of drugs.
  • DelveInsight’s Esophageal Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Esophageal Cancer treatment.
  • The leading Esophageal Cancer Companies working in the market include BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.
  • Promising Esophageal Cancer Therapies in the various stages of development include Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.

Stay ahead with the most recent pipeline outlook for Esophageal Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Esophageal Cancer Treatment

Esophageal Cancer Emerging Drugs Profile

  • AN-0025: Adlai Nortye

AN0025 is a clinical stage, potential first-in-class EP4 antagonist designed to modulate tumor microenvironment. It blocks the PGE2-EP4 signaling pathway to inhibit PGE2-mediated immunosuppression in the tumor microenvironment. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Esophageal Cancer. 

  • Tucatinib: Seagen

Tucatinib (TUKYSA®) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth.HER2 is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. In preclinical in vitro studies, TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. In preclinical and clinical studies, TUKYSA inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab has also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone. Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Esophageal Cancer. 

  • APX 005M: Apexigen

APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, esophageal and gastroesophageal junction cancers, melanoma, non-small cell lung cancer, rectal cancer and sarcoma in various combinations with immunotherapy, chemotherapy, radiation therapy or a cancer vaccine.

Explore groundbreaking therapies and clinical trials in the Esophageal Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Esophageal Cancer Drugs

Esophageal Cancer Companies

BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others. 

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal 

Esophageal Cancer Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Unveil the future of Esophageal Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Esophageal Cancer Market Drivers and Barriers

Scope of the Esophageal Cancer Pipeline Report

  • Coverage- Global
  • Esophageal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Esophageal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Esophageal Cancer Companies- BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.
  • Esophageal Cancer Therapies-Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.

Get the latest on Esophageal Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Esophageal Cancer Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Esophageal Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Esophageal Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug Name : Company Name
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase II/III)
  11. Tucatinib: Seagen
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. APX 005M: Apexigen
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name : Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Esophageal Cancer Key Companies
  21. Esophageal Cancer Key Products
  22. Esophageal Cancer – Unmet Needs
  23. Esophageal Cancer – Market Drivers and Barriers
  24. Esophageal Cancer – Future Perspectives and Conclusion
  25. Esophageal Cancer Analyst Views
  26. Esophageal Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Esophageal Cancer Pipeline 2024 | BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company

Monoclonal Antibody (mABs) Therapeutics Market worth $497.5 billion by 2029 | MarketsandMarkets™

“Key players in the monoclonal antibody therapeutics market are F. Hoffmann-La Roche Ltd (Switzerland), Abbvie Inc. (US), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US)”
Browse 365 market data Tables and 58 Figures spread through 350 Pages and in-depth TOC on “Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) – Global Forecast to 2029

 Monoclonal Antibody (mABs) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by MarketsandMarkets™. The monoclonal antibody therapeutics market is primarily driven by factors such as increasing prevalence of chronic diseases like cancer, autoimmune disorders, and infectious diseases. Technological advancements in antibody engineering and production processes also contribute significantly. Additionally, growing investments in research and development, coupled with expanding applications in personalized medicine, drive market growth. For example, drugs like rituximab (used for lymphoma and leukemia) and trastuzumab (used for breast cancer) exemplify the success and potential of monoclonal antibody therapeutics.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=115323820

 

The In-Vitro accounted for the largest share of production method in the monoclonal antibody therapeutics market in 2023.

By Production Method, the monoclonal antibody therapeutics market is segmented into in-vitro and in-vivo. In-Vitro for the largest share of the monoclonal antibody therapeutics market in 2023. The in vitro production method for monoclonal antibody therapeutics is propelled by factors such as scalability, cost-effectiveness, and reduced risk of contamination compared to traditional in vivo methods. Advancements in cell culture technologies and bioprocessing techniques have enhanced productivity and consistency. Moreover, regulatory agencies favor in vitro production for its quality control advantages.

The human source segment is expected to grow at a higher rate during the forecast period.

Based on sources, monoclonal antibody therapeutics market is segmented into human, humanized, chimeric and other sources. In 2023, human segment accounted for the largest share of the monoclonal antibody therapeutics market and humanized segment is expected to grow at a higher growth rate during the forecast period of 2024-2029. The human source monoclonal antibody therapeutics market is propelled by factors such as reduced immunogenicity, improved efficacy, and enhanced safety profiles compared to non-human sources. Increasing demand for precision medicine and personalized therapies also drives market growth. Technological advancements in antibody discovery platforms, such as phage display and transgenic mice, further accelerate development timelines. Examples include adalimumab (Humira) for autoimmune diseases and pembrolizumab (Keytruda) for cancer, highlighting the success and potential of human-sourced monoclonal antibody therapeutics in addressing diverse medical needs.

The autoimmune and inflammatory segment accounted for the largest share of the therapy area segment in the monoclonal antibody therapeutics market in 2023.

Based on therapy area the monoclonal antibody therapeutics market is segmented into autoimmune & inflammatory disorders, oncology, hematology, opthalmology and other therapy area. In 2023, autoimmune & inflammatory diseases segment dominated the monoclonal antibody therapeutics market. The monoclonal antibody therapeutics market for autoimmune and inflammatory diseases and cancer is driven by several factors. For autoimmune and inflammatory diseases, increasing prevalence, unmet medical needs, and advancements in targeted therapies propel market growth. Examples include adalimumab (Humira) for rheumatoid arthritis and infliximab (Remicade) for Crohn’s disease. In cancer, rising incidence rates, expanding treatment options, and personalized medicine approaches contribute to market expansion.

The hospitals accounted for the largest share of end user in the monoclonal antibody therapeutics market in 2023.

By end user, hospitals, long-term care facilities, and other end users. In 2023, hospitals accounted for the largest share of the monoclonal antibody therapeutics market. The monoclonal antibody therapeutics market for hospitals is driven by factors such as increasing patient admissions, advancements in healthcare infrastructure, and growing demand for advanced treatments. Examples include hospitals incorporating monoclonal antibody therapies like bevacizumab (Avastin) for cancer into their treatment regimens, enhancing patient care and outcomes

Europe is likely to grow at significant CAGR during forecast period of 2024-2029.

The monoclonal antibody therapeutics market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. North America dominated the monoclonal antibody therapeutics market. Europe’s accelerated growth is attributed to several factors. Robust healthcare infrastructure, favorable government policies, increased research and development investments, rising prevalence of chronic diseases, and expanding adoption of innovative medical technologies. Additionally, collaborations between academia, industry, and regulatory bodies further drive advancements in healthcare, propelling Europe towards faster-paced growth in various medical sectors.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=115323820

Monoclonal Antibody (mABs) Therapeutics Market Dynamics:

Drivers:

  1. Advancements in biotechnology and genetic engineering
  2. Increasing demand for personalized medicine
  3. Growing product pipeline of mAb therapeutics

Restraints:

  1. Stringent regulatory approval process
  2. High cost of mAb treatments

Opportunities:

  1. Innovative therapeutic indications
  2. Rising technological advancements in antibody engineering

Challenge:

  1. Rising development & production costs

Key Market Players of Monoclonal Antibody (mABs) Therapeutics Industry:

Key players in the monoclonal antibody therapeutics market are F. Hoffmann-La Roche Ltd (Switzerland), Abbvie Inc. (US), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Bristol Myers Squibb Company (US), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Amgen Inc. (US), Takeda Pharmaceutical Company Limited (Japan), GSK plc. (UK), Eli Lilly and Company (US), Regeneron Pharmaceuticals Inc. (US), and among others.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives- 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East & Africa- 5%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=115323820

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/monoclonal-antibody-mabs-therapeutics-market-115323820.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Monoclonal Antibody (mABs) Therapeutics Market worth $497.5 billion by 2029 | MarketsandMarkets™

Natural Language Understanding Market Size, Revenue, Top Key Companies, Industry Analysis, Advance Technology, Future Development & Forecast – 2029

“Microsoft (US), Google (US), IBM (US), AWS (US), Meta (US), SAS Institute, Oracle (US), Salesforce (US), OpenAI (US), SoundHound AI (US), IQVIA (US), LivePerson (US), Haptik (India), Kapiche (Australia), Rasa (US), MindMeld (US), Hugging Face (US), Conversica (US), Expert.ai (Italy).”
Natural Language Understanding (NLU) Market Size, Share, Growth Analysis, By Offering (Solutions, Services), Type, Application (Machine Translation, Chatbots & Virtual Assistants, Sentiment Analysis, Data Capture) – Global Industry Forecast to 2029.

The natural language understanding (NLU) market is expected to grow from USD 19.2 billion in 2024 to USD 62.9 billion in 2029, at a CAGR of 26.8% during the forecast period. The natural language understanding market is driven growing consumer demand for personalized and intuitive interactions, increased productivity and reduced call duration in contact centers, rising demand for brand messaging and exponential growth of unstructured text data.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=204151413  

By offering, the services segment to account for higher CAGR during the forecast period.

The demand for services in the NLU market is rapidly increasing, making it the fastest-growing segment. These services include consulting, training, system integration and implementation, and support & maintenance, all aimed at helping organizations effectively deploy NLU solutions. As businesses look to customize NLU solutions to their unique requirements, integrate them with current systems, and enhance their performance, specialized services are becoming essential. Furthermore, with the continuous growth in unstructured data complexity, there is a rising need for services that can assist in data preprocessing, annotation, and quality assurance to maintain the accuracy and reliability of NLU models.

By Vertical, BFSI is expected to hold the largest market size for the year 2024.

The vertical market in the natural language understanding (NLU) market is set to be dominated by the Banking, Financial Services, and Insurance (BFSI) sector. This sector holds the largest share due to various factors specific to the BFSI industry. These factors include the growing demand for personalized customer experiences, improved fraud detection and risk assessment capabilities, and the necessity for efficient communication channels. NLU technologies empower BFSI institutions to automate customer interactions through chatbots and virtual assistants, offering real-time assistance, personalized recommendations, and seamless transaction experiences. Sentiment analysis tools are also utilized by NLU that provide financial institutions with the ability to comprehend customer feedback and sentiment, enabling them to customize products and services accordingly. NLU plays a vital role in compliance and regulatory reporting by analyzing and extracting insights from extensive amounts of unstructured data, such as legal documents and customer communications.

By Application, machine translation is projected to grow at the highest CAGR during the forecast period.

The machine translation application segment is experiencing rapid growth in the natural language understanding (NLU) market due to the increasing demand for seamless communication across languages and cultures. As businesses expand globally and engage with diverse audiences, there is a growing need for accurate and effective translation solutions that can overcome language barriers. Machine translation applications utilize advanced NLU techniques, such as neural machine translation (NMT) and deep learning algorithms, to provide high-quality translations that are more accurate and proficient. The emergence of multilingual digital platforms and global collaboration efforts has further propelled the adoption of machine translation applications, leading to innovation and advancements in NLU technology.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=204151413  

Unique Features in the Natural Language Understanding Market

NLU capabilities have substantially progressed with the creation and application of complex language models such as Google’s BERT and OpenAI’s GPT-4. These models are very useful for a variety of applications, such as chatbots and content generation, because they can comprehend and produce text that is similar to that of a human. They can comprehend context, subtlety, and even irony in human language since they have been educated on enormous datasets.

NLU technology is becoming more and more industry-specific. For example, NLU is used in the financial and healthcare sectors for sentiment analysis and risk assessment, and in medical records and patient inquiries.

One critical component of contemporary NLU systems is their multilingual understanding and processing capabilities. Businesses are spending money on bilingual models in order to serve a worldwide clientele.

Applications for virtual assistants and customer support in particular are using real-time NLU processing more and more. This feature enables systems to comprehend questions and provide prompt answers, resulting in a flawless user experience. Improvements in edge AI and cloud computing, which lower latency and boost speed, make real-time processing possible.

Deep learning and neural networks are used by modern NLU systems to increase context and intent understanding accuracy. These systems are capable of managing intricate queries, clarifying meanings, and offering pertinent answers. NLU models can learn from fresh data and interactions over time using continuous learning techniques.

Major Highlights of the Natural Language Understanding Market

The market for natural language understanding (NLU) is expanding significantly because to the rising demand for cutting-edge AI solutions across a range of industries. Investment in NLU technologies keeps growing as companies realize how valuable AI is for enhancing customer interactions, streamlining workflows, and extracting insights from massive amounts of unstructured data.

The development of advanced AI models, including Google’s BERT and OpenAI’s GPT-4, has significantly improved the performance of NLU systems. By using deep learning techniques, these models are able to produce text that is similar to that of a human, which improves accuracy and contextual awareness in language processing.

NLU technologies are becoming more and more customized to fit the particular requirements of many sectors. NLU is utilized in healthcare to help with patient communication and the interpretation of medical records.

Given the globalization of business, multilingual comprehension and processing are essential. Strong multilingual capabilities provided by contemporary NLU systems allow businesses to interact with a wide range of international customers. Additionally, smooth data analysis and communication between various linguistic groups is made possible by cross-language support

In applications such as virtual assistants and customer support, real-time natural language understanding is quickly becoming a regular function. Instantaneous comprehension and reaction to customer inquiries is made possible by this capacity, greatly improving the user experience. Improvements in edge AI and cloud computing technologies enable real-time processing.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=204151413  

Top Companies in the Natural Language Understanding Market

The major NLU solutions and service providers Microsoft (US), Google (US), IBM (US), AWS (US), Meta (US), SAS Institute, Oracle (US), Salesforce (US), OpenAI (US), SoundHound AI (US), IQVIA (US), LivePerson (US), Haptik (India), Kapiche (Australia), Rasa (US), MindMeld (US), Hugging Face (US), Conversica (US), Expert.ai (Italy), Verbio Technologies (Spain), Wolfram (US), Cortical.io (Austria), Omilia (Cyprus), Cognigy (Germany), Plasticity (US), Afforai (US), Tune AI (US), Vebrit.ai (US), Synthesys (UK), Picovoice (Canada), Symbl.ai (US), Tisane Labs (Singapore), Prosa.ai (Indonesia), Abacus.AI (US), Forethought (US). These companies have used both organic and inorganic growth strategies such as product launches, acquisitions, and partnerships to strengthen their position in the NLU market.

Microsoft is a global leader in providing software products and diverse licensing suites, developing and supporting a wide array of software, services, devices, and solutions. Microsoft offers a wide range of AI-powered services and products through its Azure platform. Azure AI Language provides comprehensive NLU capabilities, including text analysis, sentiment analysis, key phrase extraction, and text summarization. The company also supports developers and businesses in integrating NLU into applications with tools like Azure AI Content Safety and Azure AI Search, enhancing content moderation and search functionalities. Language Understanding Intelligent Service (LUIS) provides a robust platform for building custom NLU models, enabling developers to create sophisticated language understanding applications. The acquisition of Nuance Communications adds significant value to its NLU offerings such as Mix NLU platform and Nuance Recognizer. Microsoft’s robust infrastructure and continuous innovation in AI technologies make it a key contributor to advancements in the NLU market.

Google is a major contributor to the Natural Language Understanding (NLU) market, utilizing its advanced AI capabilities and extensive data resources. With products like Google Assistant, Google Translate, and the Cloud Natural Language API, Google enables businesses to offer personalized, intuitive interactions and enhance customer experience. The company’s continuous investment in research and development, coupled with its extensive computational infrastructure, allows it to analyze and analyze large volumes of unstructured text data efficiently. This drives the performance in various applications, including customer service automation, sentiment analysis, and content categorization, making Google a key leader in the evolving NLU landscape.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/natural-language-understanding-nlu-market-204151413.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Natural Language Understanding Market Size, Revenue, Top Key Companies, Industry Analysis, Advance Technology, Future Development & Forecast – 2029

Non-Hodgkin Lymphoma Pipeline 2024 | Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences

DelveInsight’s, “Non-Hodgkin Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin Lymphoma Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Non-Hodgkin Lymphoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Non-Hodgkin Lymphoma Pipeline Outlook

Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report

  • July 2024:- Genmab– The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of GEN3017 as a monotherapy in participants with relapsed or refractory (R/R) CD30-expressing lymphomas.
  • July 2024:- Bristol-Myers Squibb– The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader (LDD) of BCL6 (BCL6 LDD), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.
  • DelveInsight’s Non-Hodgkin Lymphoma Pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Non-Hodgkin Lymphoma treatment.
  • The leading Non-Hodgkin Lymphoma Companies such as Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others.
  • Promising Non-Hodgkin Lymphoma Pipeline Therapies such as Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others.

Stay ahead with the most recent pipeline outlook for Non-Hodgkin Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non-Hodgkin Lymphoma Treatment

Non-Hodgkin Lymphoma Emerging Drugs Profile

  • Mosunetuzumab: Hoffmann-la Roche

Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3e), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies. 

  • Tisagenlecleucel: Novartis

Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy that involves genetically modified autologous T cells isolated from each individual patient. The reprogramming of the patient’s T cells uses a lentiviral vector to encode an anti-CD19 chimeric antigen receptor (CAR). 

  • Capivasertib: AstraZeneca

Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. Currently, it is in Phase II stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma.

  • BI-1206: BioInvent

BI-1206 is a high-affinity monoclonal antibody that selectivity binds to Fc?RIIB (CD32B), the only inhibitory member of the Fc?R family. Fc?RIIB is overexpressed in several forms of NHL and overexpression has been associated with poor prognosis in difficult-to treat forms of NHL, such as mantle cell lymphoma. By blocking Fc?RIIB, BI-1206 is expected to recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of these diseases. In January 2023, positive data was presented from the ongoing clinical Phase I/IIa study of BI-1206 in combination with rituximab for the treatment of non-Hodgkin’s lymphoma (NHL). Data suggest that BI-1206 restores activity of rituximab in relapsed NHL patients.

  • HMPL-760: Hutchmed

HMPL-760 is an investigational, highly selective, non-covalent, third-generation inhibitor of BTK, both wild-type and C481S mutant enzymes, with pre-clinical data suggesting high target specificity and higher potency versus first generation BTK inhibitors. BTK C481S mutation plays an important role in resistance to certain BTK inhibitors.

Explore groundbreaking therapies and clinical trials in the Non-Hodgkin Lymphoma Pipeline. Access DelveInsight’s detailed report now! @ New Non-Hodgkin Lymphoma Drugs

Non-Hodgkin Lymphoma Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.

Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Unveil the future of Non-Hodgkin Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Non-Hodgkin Lymphoma Market Drivers and Barriers

Scope of the Non-Hodgkin Lymphoma Pipeline Report

  • Coverage- Global
  • Non-Hodgkin Lymphoma Companies- Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others.
  • Non-Hodgkin Lymphoma Pipeline Therapies- Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others.
  • Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Non-Hodgkin Lymphoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Non-Hodgkin Lymphoma Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Non-Hodgkin Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non-Hodgkin Lymphoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Tisagenlecleucel: Novartis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Capivasertib: AstraZeneca
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. BI-1206: BioInvent
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. HMPL-760: Hutchmed
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. Product Name: Company Name
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Non-Hodgkin Lymphoma Key Companies
  24. Non-Hodgkin Lymphoma Key Products
  25. Non-Hodgkin Lymphoma- Unmet Needs
  26. Non-Hodgkin Lymphoma- Market Drivers and Barriers
  27. Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
  28. Non-Hodgkin Lymphoma Analyst Views
  29. Non-Hodgkin Lymphoma Key Companies
  30. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Hodgkin Lymphoma Pipeline 2024 | Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences